🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to announce new data at the 2024 European Hematology Association Congress on our CRISPR/Cas9 gene-edited treatment, along with new health and economics outcomes research highlighting disease burdens. Learn more about our work: vrtx.com/?utm_source=tw…

We are pleased to share new data from our Phase 1/2 clinical trial for our investigational type 1 diabetes treatment at the 2024 @amdiabetesassn Scientific Sessions. Learn more: news.vrtx.com/news-releases/…

#Breaking: The U.S. FDA has accepted the application and granted Priority Review for our fifth investigational CFTR modulator #CysticFibrosis. Learn more: news.vrtx.com/press-releases…

Extended reimbursement agreement with the Ministry of Health in #Montegro. Since July 1 eligible children living with #CysticFibrosis ages 2 and older have broad access to one of our medicines.

We are excited to share that the FDA has accepted and granted priority review to the New Drug Application (NDA) submission for our investigational acute pain medicine. Learn more: news.vrtx.com/news-releases/…

#Breaking Health Canada grants marketing authorization of our treatment for #SickleCellDisease and #BetaThalassemia.

Today the Mexican Federal Regulatory Authority (COFEPRIS) approved one of our latest cystic fibrosis (CF) medicines in Mexico. This marks an important step toward our goal of treating all people with CF.

First reimbursement agreement in #Lithuania: Since October 1st, 2024, eligible people living with #CysticFibrosis have had reimbursed access to one of our #CysticFibrosis therapies. All EU Member States now have agreements in place for patients to access medicines that treat the

Today we announced that we will present pivotal Phase 3 data about our investigational pain program at the ASA® annual meeting in Philly. Learn more: news.vrtx.com/news-releases/…

We are excited to share new data from multiple investigational kidney disease programs at the 2024 American Society of Nephrology Week Congress. Learn more: investors.vrtx.com/news-releases/… #KidneyWk

At the ASH Annual Meeting this weekend, we are pleased to share new data on our gene-edited therapy. Learn more: vrtx.com/?utm_source=tw…

#Breaking: The U.S. FDA approves a label extension for #CysticFibrosis. We are excited to make this treatment available to more eligible patients. Learn more: vrtx.com

#Breaking: The U.S. FDA has approved our newest treatment for cystic fibrosis. Learn more: news.vrtx.com/press-releases

Extended reimbursement agreement with the National Health Insurance in #Romania: Since the beginning of December eligible children living with #CysticFibrosis ages 2 years and older will have broad access to one of our medicines.

Extended reimbursement agreement with the National Health Insurance Fund in #Bulgaria: Since January 1 eligible children living with #CysticFibrosis ages 1 year and older will have broad access to some of our medicines.

#Breaking: The U.S. FDA approves our treatment for moderate-to-severe acute pain in adults. This is the first new class of pain medicine to be approved in over 20 years. Learn more: news.vrtx.com/news-releases/…

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step

Today the European Commission approved the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step towards our goal of treating all people with CF.

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our fifth cystic fibrosis (CF) medicine. This is an important step towards our goal of treating all people living with CF.

Extended reimbursement agreement with the health authorities of #Slovenia: eligible children living with #CysticFibrosis ages 1 year and older will now have broad access to some of our medicines.